[
    {
        "source_page": 3,
        "anchor_text": "See NCCN Categories and Consensus.",
        "destination_page": 120
    },
    {
        "source_page": 3,
        "anchor_text": "NCCN Categories of Preference.",
        "destination_page": 120
    },
    {
        "source_page": 3,
        "anchor_text": "See NCCN Preference.",
        "destination_page": 120
    },
    {
        "source_page": 3,
        "anchor_text": "NCCN Non-Small Cell Lung Cancer Summary of the Guidelines Updates",
        "destination_page": 4
    },
    {
        "source_page": 3,
        "anchor_text": "Lung Cancer Prevention and Screening (PREV-1) Clinical Presentation and Risk Assessment (DIAG-1)",
        "destination_page": 17
    },
    {
        "source_page": 3,
        "anchor_text": "Lung Cancer Prevention and Screening (PREV-1) Clinical Presentation and Risk Assessment (DIAG-1) Initial Evaluation and Clinical Stage (NSCL-1)",
        "destination_page": 18
    },
    {
        "source_page": 3,
        "anchor_text": "Clinical Presentation and Risk Assessment (DIAG-1) Initial Evaluation and Clinical Stage (NSCL-1) Evaluation and Treatment:",
        "destination_page": 24
    },
    {
        "source_page": 3,
        "anchor_text": "Evaluation and Treatment: Stage IA (peripheral T1abc, N0) (NSCL-2) Stage IB (peripheral T2a, N0), Stage I (central",
        "destination_page": 25
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IA (peripheral T1abc, N0) (NSCL-2) Stage IB (peripheral T2a, N0), Stage I (central T1abc–T2a, N0), Stage II (T1abc–T2ab, N1; T2b, N0), Stage IIB (T3, N0), and Stage",
        "destination_page": 26
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IB (peripheral T2a, N0), Stage I (central T1abc–T2a, N0), Stage II (T1abc–T2ab, N1; T2b, N0), Stage IIB (T3, N0), and Stage IIIA (T3, N1) (NSCL-3) Stage IIB (T3 invasion, N0) and Stage IIIA (T4 invasion, N0–1; T3, N1; T4, N0–1) (NSCL-5)",
        "destination_page": 26
    },
    {
        "source_page": 3,
        "anchor_text": "Stage II (T1abc–T2ab, N1; T2b, N0), Stage IIB (T3, N0), and Stage IIIA (T3, N1) (NSCL-3) Stage IIB (T3 invasion, N0) and Stage IIIA (T4 invasion, N0–1; T3, N1; T4, N0–1) (NSCL-5) Stage IIIA (T1–2, N2); Stage IIIB (T3, N2) (NSCL-8)",
        "destination_page": 29
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IIB (T3 invasion, N0) and Stage IIIA (T4 invasion, Stage IIIA (T1–2, N2); Stage IIIB (T3, N2) (NSCL-8) Separate Pulmonary Nodule(s) (Stage IIB, IIIA, IV);",
        "destination_page": 32
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2) (NSCL-8) Separate Pulmonary Nodule(s) (Stage IIB, IIIA, IV); Stage IIIA ipsilateral non-primary lobe (T4, N0-N1); Stage",
        "destination_page": 32
    },
    {
        "source_page": 3,
        "anchor_text": "Separate Pulmonary Nodule(s) (Stage IIB, IIIA, IV); Stage IIIA ipsilateral non-primary lobe (T4, N0-N1); Stage IV (contralateral lung) (NSCL-8) Multiple Lung Cancers (N0–1) (NSCL-12)",
        "destination_page": 32
    },
    {
        "source_page": 3,
        "anchor_text": "[链接在非文本对象上]",
        "destination_page": 32
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IIIA ipsilateral non-primary lobe (T4, Multiple Lung Cancers (N0–1) (NSCL-12) Stage IIIB (T1–2, N3); Stage IIIC (T3, N3)",
        "destination_page": 36
    },
    {
        "source_page": 3,
        "anchor_text": "Multiple Lung Cancers (N0–1) (NSCL-12) Stage IIIB (T1–2, N3); Stage IIIC (T3, N3) (NSCL-13) Stage IIIB (T4, N2); Stage IIIC (T4, N3); Stage IVA, M1a:",
        "destination_page": 37
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IIIB (T1–2, N3); Stage IIIC (T3, N3) (NSCL-13) Stage IIIB (T4, N2); Stage IIIC (T4, N3); Stage IVA, M1a: Pleural or Pericardial Effusion (NSCL-14) Stage IVA, M1b and Stage IVB, M1c (definitive therapy for solitary or limited metastases) (NSCL-15)",
        "destination_page": 38
    },
    {
        "source_page": 3,
        "anchor_text": "Stage IIIB (T4, N2); Stage IIIC (T4, N3); Stage IVA, M1a: Pleural or Pericardial Effusion (NSCL-14) Stage IVA, M1b and Stage IVB, M1c (definitive therapy for solitary or limited metastases) (NSCL-15) Surveillance After Completion of Definitive Therapy (NSCL-17)",
        "destination_page": 39
    },
    {
        "source_page": 3,
        "anchor_text": "• Stage IVA, M1b and Stage IVB, M1c (definitive therapy for solitary Surveillance After Completion of Definitive Therapy (NSCL-17) Therapy for Recurrence and Metastasis (local therapy and control",
        "destination_page": 41
    },
    {
        "source_page": 3,
        "anchor_text": "Surveillance After Completion of Definitive Therapy (NSCL-17) Therapy for Recurrence and Metastasis (local therapy and control of symptoms) (NSCL-18) Advanced or Metastatic Disease (systemic therapy planned) (NSCL-19)",
        "destination_page": 42
    },
    {
        "source_page": 3,
        "anchor_text": "Therapy for Recurrence and Metastasis (local therapy and control of symptoms) Advanced or Metastatic Disease (systemic therapy planned) (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 3,
        "anchor_text": "Principles of Pathologic Review (NSCL-A) Principles of Surgical Therapy (NSCL-B)",
        "destination_page": 64
    },
    {
        "source_page": 3,
        "anchor_text": "Principles of Pathologic Review (NSCL-A) Principles of Surgical Therapy (NSCL-B) Principles of Radiation Therapy (NSCL-C)",
        "destination_page": 68
    },
    {
        "source_page": 3,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B) Principles of Radiation Therapy (NSCL-C) Principles of Image-Guided Thermal Ablation",
        "destination_page": 74
    },
    {
        "source_page": 3,
        "anchor_text": "Principles of Radiation Therapy (NSCL-C) Principles of Image-Guided Thermal Ablation Therapy (NSCL-D) Perioperative Systemic Therapy (NSCL-E)",
        "destination_page": 84
    },
    {
        "source_page": 3,
        "anchor_text": "Image-Guided Thermal Ablation Systemic Therapy (NSCL-E) Chemoradiation Regimens (NSCL-F)",
        "destination_page": 85
    },
    {
        "source_page": 3,
        "anchor_text": "Perioperative Systemic Therapy (NSCL-E) Concurrent Chemoradiation Regimens (NSCL-F) Cancer Survivorship Care (NSCL-G)",
        "destination_page": 91
    },
    {
        "source_page": 3,
        "anchor_text": "Concurrent Chemoradiation Regimens Cancer Survivorship Care (NSCL-G) Principles of Molecular and Biomarker",
        "destination_page": 93
    },
    {
        "source_page": 3,
        "anchor_text": "Cancer Survivorship Care (NSCL-G) Principles of Molecular and Biomarker Analysis (NSCL-H) Emerging Biomarkers to Identify Novel Therapies for Patients",
        "destination_page": 95
    },
    {
        "source_page": 3,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H) Emerging Biomarkers to Identify Novel Therapies for Patients with Metastatic NSCLC (NSCL-I) Molecular and Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)",
        "destination_page": 103
    },
    {
        "source_page": 3,
        "anchor_text": "Emerging Biomarkers to Identify Novel Therapies for Patients with Metastatic NSCLC (NSCL-I) Molecular and Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J) Systemic Therapy for Advanced or Metastatic Disease (NSCL-K)",
        "destination_page": 104
    },
    {
        "source_page": 3,
        "anchor_text": "Molecular and Biomarker-Directed Therapy for Advanced or Metastatic Systemic Therapy for Advanced or Metastatic Disease (NSCL-K)",
        "destination_page": 110
    },
    {
        "source_page": 3,
        "anchor_text": "Staging (ST-1)",
        "destination_page": 115
    },
    {
        "source_page": 4,
        "anchor_text": "NSCL-19 • Biomarker",
        "destination_page": 43
    },
    {
        "source_page": 4,
        "anchor_text": "tissue conservation. NSCL-J 1 of 6 • c-Met/MET (≥50%",
        "destination_page": 104
    },
    {
        "source_page": 4,
        "anchor_text": "Telisotuzumab NSCL-J 6 of 6 • Reference 54",
        "destination_page": 109
    },
    {
        "source_page": 4,
        "anchor_text": "3011. NSCL-K 4 of 5 • Systemic Therapy",
        "destination_page": 113
    },
    {
        "source_page": 4,
        "anchor_text": "NSCL-30 • First-Line",
        "destination_page": 54
    },
    {
        "source_page": 4,
        "anchor_text": "Taletrectinib NSCL-J 5 of 6 • Reference added:",
        "destination_page": 108
    },
    {
        "source_page": 5,
        "anchor_text": "NSCL-27 • First-Line",
        "destination_page": 51
    },
    {
        "source_page": 5,
        "anchor_text": "◊Ensartinib NSCL-28 • Subsequent",
        "destination_page": 52
    },
    {
        "source_page": 5,
        "anchor_text": "Continuation NSCL-29 • Subsequent",
        "destination_page": 53
    },
    {
        "source_page": 5,
        "anchor_text": "NSCL-E 2 of 6 • Neoadjuvant Systemic",
        "destination_page": 86
    },
    {
        "source_page": 6,
        "anchor_text": "PREV-1 • Bullet 2",
        "destination_page": 17
    },
    {
        "source_page": 6,
        "anchor_text": "predisposition—to DIAG-A 3 of 3 • Bullet 1, sub-bullet",
        "destination_page": 23
    },
    {
        "source_page": 6,
        "anchor_text": "if these NSCL-1 • Clinical",
        "destination_page": 24
    },
    {
        "source_page": 6,
        "anchor_text": "Stage NSCL-2 • Negative",
        "destination_page": 25
    },
    {
        "source_page": 6,
        "anchor_text": "about SABR NSCL-3 • Pretreatment",
        "destination_page": 26
    },
    {
        "source_page": 6,
        "anchor_text": "adjuvant NSCL-4 • Stage IB",
        "destination_page": 27
    },
    {
        "source_page": 7,
        "anchor_text": "macroscopic NSCL-5 • Clinical",
        "destination_page": 29
    },
    {
        "source_page": 7,
        "anchor_text": "Positive NSCL-6 • Clinical",
        "destination_page": 30
    },
    {
        "source_page": 7,
        "anchor_text": "◊Durvalumab NSCL-7 • Clinical",
        "destination_page": 31
    },
    {
        "source_page": 7,
        "anchor_text": "Preferred NSCL-8 • Clinical",
        "destination_page": 32
    },
    {
        "source_page": 7,
        "anchor_text": "◊Stage NSCL-9 • T1, N0,",
        "destination_page": 33
    },
    {
        "source_page": 7,
        "anchor_text": "Definitive NSCL-10 • T1–3, N1",
        "destination_page": 34
    },
    {
        "source_page": 8,
        "anchor_text": "NSCL-11 • Separate",
        "destination_page": 35
    },
    {
        "source_page": 8,
        "anchor_text": "interventional NSCL-13 • Pretreatment",
        "destination_page": 37
    },
    {
        "source_page": 8,
        "anchor_text": "◊Durvalumab NSCL-15 • Limited progression",
        "destination_page": 39
    },
    {
        "source_page": 8,
        "anchor_text": "• Limited progression NSCL-17 • Surveillance",
        "destination_page": 41
    },
    {
        "source_page": 8,
        "anchor_text": "Bullet 5 NSCL-18 • Distant metastases",
        "destination_page": 42
    },
    {
        "source_page": 8,
        "anchor_text": "Pleural NSCL-19 • Biomarker",
        "destination_page": 43
    },
    {
        "source_page": 9,
        "anchor_text": "NSCL-20 • Testing Results",
        "destination_page": 44
    },
    {
        "source_page": 9,
        "anchor_text": "NRG1 NSCL-21 • First-Line",
        "destination_page": 45
    },
    {
        "source_page": 9,
        "anchor_text": "NSCL-33, NSCL-22 • Subsequent",
        "destination_page": 46
    },
    {
        "source_page": 10,
        "anchor_text": "NSCL-27 • First-Line",
        "destination_page": 51
    },
    {
        "source_page": 10,
        "anchor_text": "Ceritinib NSCL-30 • First-Line",
        "destination_page": 54
    },
    {
        "source_page": 10,
        "anchor_text": "◊The NSCL-31 • Subsequent",
        "destination_page": 55
    },
    {
        "source_page": 10,
        "anchor_text": "Dabrafenib NSCL-33 • First-Line",
        "destination_page": 57
    },
    {
        "source_page": 10,
        "anchor_text": "◊The NSCL-34 • First-Line",
        "destination_page": 58
    },
    {
        "source_page": 11,
        "anchor_text": "NSCL-35 • First-Line",
        "destination_page": 59
    },
    {
        "source_page": 11,
        "anchor_text": "• New page NSCL-38 • Performance",
        "destination_page": 62
    },
    {
        "source_page": 11,
        "anchor_text": "administration NSCL-B • Resection",
        "destination_page": 69
    },
    {
        "source_page": 12,
        "anchor_text": "NSCL-B 3 of 6 • Margins and Nodal",
        "destination_page": 70
    },
    {
        "source_page": 12,
        "anchor_text": "Bullet 1: Added NSCL-B 5 of 6 • Survey data updated",
        "destination_page": 72
    },
    {
        "source_page": 12,
        "anchor_text": "3 Lim E, Batchelor NSCL-C 3 of 10 • SABR for Node-Negative",
        "destination_page": 76
    },
    {
        "source_page": 12,
        "anchor_text": "cm). Adjuvant NSCL-C 7 of 10 • Normal Tissue",
        "destination_page": 80
    },
    {
        "source_page": 12,
        "anchor_text": "◊V40 ≤20% NSCL-C 9 of 10 • Reference 46 added:",
        "destination_page": 82
    },
    {
        "source_page": 12,
        "anchor_text": "non-small cell NSCL-E 1 of 6 • Neoadjuvant Systemic",
        "destination_page": 85
    },
    {
        "source_page": 12,
        "anchor_text": "induction neoadjuvant NSCL-E 4 of 6 • Adjuvant Chemotherapy",
        "destination_page": 88
    },
    {
        "source_page": 13,
        "anchor_text": "NSCL-E 5 of 6 • Systemic Therapy",
        "destination_page": 89
    },
    {
        "source_page": 13,
        "anchor_text": "mutations NSCL-F 1 of 2 • Consolidation",
        "destination_page": 91
    },
    {
        "source_page": 14,
        "anchor_text": "NSCL-G • Section",
        "destination_page": 93
    },
    {
        "source_page": 14,
        "anchor_text": "Statement. Am NSCL-H 1 of 8 • Bullet 3 added:",
        "destination_page": 95
    },
    {
        "source_page": 14,
        "anchor_text": "throughout) NSCL-H 2 of 8 • Bullet removed:",
        "destination_page": 96
    },
    {
        "source_page": 15,
        "anchor_text": "NSCL-H 3 of 8 • EGFR (Epidermal",
        "destination_page": 97
    },
    {
        "source_page": 15,
        "anchor_text": "also acceptable NSCL-H 4 of 8 • ALK (anaplastic",
        "destination_page": 98
    },
    {
        "source_page": 15,
        "anchor_text": "for this indication. NSCL-H 6 of 8 • Section added",
        "destination_page": 100
    },
    {
        "source_page": 15,
        "anchor_text": "oncogenic drivers NSCL-H 8 of 8 • Section added",
        "destination_page": 102
    },
    {
        "source_page": 15,
        "anchor_text": "• Section NSCL-I • Genetic",
        "destination_page": 103
    },
    {
        "source_page": 16,
        "anchor_text": "NSCL-J 1 of 6 • EGFR S768I,",
        "destination_page": 104
    },
    {
        "source_page": 16,
        "anchor_text": "Fam-trastuzumab NSCL-J 6 of 6 • Reference 44",
        "destination_page": 109
    },
    {
        "source_page": 16,
        "anchor_text": "overexpressing NSCL-K 1 of 5 • Recommendations",
        "destination_page": 110
    },
    {
        "source_page": 16,
        "anchor_text": "Category 1 removed NSCL-K 4 of 5 • Fam-trastuzumab",
        "destination_page": 113
    },
    {
        "source_page": 18,
        "anchor_text": "experience in the diagnosis of lung cancer. Principles of Diagnostic Evaluation (DIAG-A 1 of 3). The most important radiologic factor is change or stability",
        "destination_page": 21
    },
    {
        "source_page": 18,
        "anchor_text": "Solid nodules Follow-up (DIAG-2)",
        "destination_page": 19
    },
    {
        "source_page": 18,
        "anchor_text": "Follow-up (DIAG-2)",
        "destination_page": 19
    },
    {
        "source_page": 18,
        "anchor_text": "Subsolid nodules Follow-up",
        "destination_page": 20
    },
    {
        "source_page": 18,
        "anchor_text": "Subsolid nodules Follow-up (DIAG-3)",
        "destination_page": 20
    },
    {
        "source_page": 18,
        "anchor_text": "Follow-up (DIAG-3)",
        "destination_page": 20
    },
    {
        "source_page": 19,
        "anchor_text": "Principles of Diagnostic Evaluation (DIAG-A 1 of 3). The most important radiologic factor is change or stability",
        "destination_page": 21
    },
    {
        "source_page": 20,
        "anchor_text": "Principles of Diagnostic Evaluation (DIAG-A 1 of 3). The most important radiologic factor is change or stability",
        "destination_page": 21
    },
    {
        "source_page": 22,
        "anchor_text": "procedure. (NSCL-2). treatment decisions",
        "destination_page": 25
    },
    {
        "source_page": 22,
        "anchor_text": "(NSCL-2 procedure to",
        "destination_page": 25
    },
    {
        "source_page": 22,
        "anchor_text": "Invasive NSCL-3). for pathologic",
        "destination_page": 26
    },
    {
        "source_page": 24,
        "anchor_text": "Principles of Pathologic Review (NSCL-A). Enhanced frailty or geriatric assessments may",
        "destination_page": 64
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-2)",
        "destination_page": 25
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-3)",
        "destination_page": 26
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-5)",
        "destination_page": 29
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-8)",
        "destination_page": 32
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-8)",
        "destination_page": 32
    },
    {
        "source_page": 24,
        "anchor_text": "(NSCL-11)",
        "destination_page": 35
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-13)",
        "destination_page": 37
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-14)",
        "destination_page": 38
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-14)",
        "destination_page": 38
    },
    {
        "source_page": 24,
        "anchor_text": "Pretreatment (NSCL-15)",
        "destination_page": 39
    },
    {
        "source_page": 24,
        "anchor_text": "metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 25,
        "anchor_text": "option through shared decision-making. Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 25,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). Image-guided thermal ablation (IGTA) therapy",
        "destination_page": 74
    },
    {
        "source_page": 25,
        "anchor_text": "radiofrequency) may be an option for select patients. See Principles of Image-Guided Thermal Ablation Therapy (NSCL-D). Prior to treatment, multidisciplinary evaluation that includes treating",
        "destination_page": 84
    },
    {
        "source_page": 25,
        "anchor_text": "(NSCL-8) (NSCL-13)",
        "destination_page": 32
    },
    {
        "source_page": 25,
        "anchor_text": "(NSCL-8) or (NSCL-13)",
        "destination_page": 37
    },
    {
        "source_page": 25,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 25,
        "anchor_text": "Surgery (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 26,
        "anchor_text": "CT scan is positive in the mediastinum, lymph Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 26,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). Prior to treatment, multidisciplinary evaluation",
        "destination_page": 74
    },
    {
        "source_page": 26,
        "anchor_text": "or difficult, that a clinical diagnosis of lung cancer Perioperative Systemic Therapy (NSCL-E). If MRI is not possible, CT of head with contrast.",
        "destination_page": 85
    },
    {
        "source_page": 26,
        "anchor_text": "Stage IIIA/IIIB (NSCL-8) Stage IIIB/IIIC (NSCL-13)",
        "destination_page": 32
    },
    {
        "source_page": 26,
        "anchor_text": "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
        "destination_page": 37
    },
    {
        "source_page": 26,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 26,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 26,
        "anchor_text": "Surgery (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 26,
        "anchor_text": "NSCL-10",
        "destination_page": 34
    },
    {
        "source_page": 27,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 27,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 27,
        "anchor_text": "(NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 27,
        "anchor_text": "(NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 27,
        "anchor_text": "(NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 27,
        "anchor_text": "(NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 28,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 28,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). Perioperative Systemic Therapy (NSCL-E).",
        "destination_page": 74
    },
    {
        "source_page": 28,
        "anchor_text": "Principles of Radiation Therapy (NSCL-C). Perioperative Systemic Therapy (NSCL-E). R0 = complete resection with negative margins,",
        "destination_page": 85
    },
    {
        "source_page": 28,
        "anchor_text": "R0 = complete resection with negative margins, R1 Concurrent Chemoradiation Regimens (NSCL-F). u Increasing size is an important variable when evaluating",
        "destination_page": 91
    },
    {
        "source_page": 28,
        "anchor_text": "NSCL-4",
        "destination_page": 27
    },
    {
        "source_page": 29,
        "anchor_text": "CT scan is positive in the mediastinum, lymph Perioperative Systemic Therapy (NSCL-E). If MRI is not possible, CT of head with contrast.",
        "destination_page": 85
    },
    {
        "source_page": 29,
        "anchor_text": "Treatment (NSCL-6)",
        "destination_page": 30
    },
    {
        "source_page": 29,
        "anchor_text": "Treatment (NSCL-7)",
        "destination_page": 31
    },
    {
        "source_page": 29,
        "anchor_text": "for Metastasis (NSCL-15) disease (NSCL-18)",
        "destination_page": 39
    },
    {
        "source_page": 29,
        "anchor_text": "(NSCL-15) or (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 29,
        "anchor_text": "Treatment (NSCL-7)",
        "destination_page": 31
    },
    {
        "source_page": 29,
        "anchor_text": "(NSCL-13) (NSCL-14)",
        "destination_page": 37
    },
    {
        "source_page": 29,
        "anchor_text": "(NSCL-13) (NSCL-14)",
        "destination_page": 38
    },
    {
        "source_page": 29,
        "anchor_text": "N2)/ (NSCL-8) (NSCL-14)",
        "destination_page": 32
    },
    {
        "source_page": 29,
        "anchor_text": "(NSCL-8) (NSCL-14)",
        "destination_page": 38
    },
    {
        "source_page": 30,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 30,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). Concurrent Chemoradiation Regimens (NSCL-F).",
        "destination_page": 74
    },
    {
        "source_page": 30,
        "anchor_text": "Principles of Radiation Therapy (NSCL-C). Concurrent Chemoradiation Regimens (NSCL-F). For patients who have received sequential chemoradiation,",
        "destination_page": 91
    },
    {
        "source_page": 30,
        "anchor_text": "Adjuvant systemic (NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 30,
        "anchor_text": "Adjuvant systemic (NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 30,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 31,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). Perioperative Systemic Therapy (NSCL-E).",
        "destination_page": 74
    },
    {
        "source_page": 31,
        "anchor_text": "Principles of Radiation Therapy (NSCL-C). Perioperative Systemic Therapy (NSCL-E). R0 = complete resection with negative margins,",
        "destination_page": 85
    },
    {
        "source_page": 31,
        "anchor_text": "R0 = complete resection with negative margins, R1 Concurrent Chemoradiation Regimens (NSCL-F). For patients who have received sequential chemoradiation,",
        "destination_page": 91
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Adjuvant (NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 31,
        "anchor_text": "Adjuvant systemic (NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 31,
        "anchor_text": "therapy (NSCL-E)",
        "destination_page": 85
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 31,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 32,
        "anchor_text": "CT scan is positive in the mediastinum, lymph Perioperative Systemic Therapy (NSCL-E). If MRI is not possible, CT of head with contrast.",
        "destination_page": 85
    },
    {
        "source_page": 32,
        "anchor_text": "Treatment (NSCL-9)",
        "destination_page": 33
    },
    {
        "source_page": 32,
        "anchor_text": "(NSCL-10)",
        "destination_page": 34
    },
    {
        "source_page": 32,
        "anchor_text": "Stage IIIB (NSCL-13)",
        "destination_page": 37
    },
    {
        "source_page": 32,
        "anchor_text": "for Metastasis (NSCL-15) disease (NSCL-18)",
        "destination_page": 39
    },
    {
        "source_page": 32,
        "anchor_text": "(NSCL-15) or (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 32,
        "anchor_text": "(NSCL-11)",
        "destination_page": 35
    },
    {
        "source_page": 32,
        "anchor_text": "(NSCL-11)",
        "destination_page": 35
    },
    {
        "source_page": 32,
        "anchor_text": "for Metastasis (NSCL-15) disease (NSCL-18)",
        "destination_page": 39
    },
    {
        "source_page": 32,
        "anchor_text": "(NSCL-15) or (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 33,
        "anchor_text": "through shared decision-making. Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 33,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). IGTA therapy (eg, cryotherapy, microwave,",
        "destination_page": 74
    },
    {
        "source_page": 33,
        "anchor_text": "IGTA therapy (eg, cryotherapy, microwave, radiofrequency) may be an Principles of Image-Guided Thermal Ablation Therapy (NSCL-D). Prior to treatment, multidisciplinary evaluation that includes treating physicians",
        "destination_page": 84
    },
    {
        "source_page": 33,
        "anchor_text": "or difficult, that a clinical diagnosis of lung cancer Perioperative Systemic Therapy (NSCL-E).",
        "destination_page": 85
    },
    {
        "source_page": 33,
        "anchor_text": "Findings (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 33,
        "anchor_text": "Findings (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 33,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 33,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 33,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 33,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 34,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 34,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). Perioperative Systemic Therapy (NSCL-E).",
        "destination_page": 74
    },
    {
        "source_page": 34,
        "anchor_text": "Principles of Radiation Therapy (NSCL-C). Perioperative Systemic Therapy (NSCL-E). Concurrent Chemoradiation Regimens (NSCL-F).",
        "destination_page": 85
    },
    {
        "source_page": 34,
        "anchor_text": "Perioperative Systemic Therapy (NSCL-E). Concurrent Chemoradiation Regimens (NSCL-F). For patients who have received sequential chemoradiation,",
        "destination_page": 91
    },
    {
        "source_page": 34,
        "anchor_text": "for Metastasis (NSCL-15) disease (NSCL-18)",
        "destination_page": 39
    },
    {
        "source_page": 34,
        "anchor_text": "(NSCL-15) or (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 34,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 34,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 34,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 34,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 34,
        "anchor_text": "Findings (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 34,
        "anchor_text": "Findings (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 34,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 34,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 35,
        "anchor_text": "pathologic confirmation. Principles of Surgical Therapy (NSCL-B). If MRI is not possible, CT of head with contrast.",
        "destination_page": 68
    },
    {
        "source_page": 35,
        "anchor_text": "If MRI is not possible, CT of head with contrast. Perioperative Systemic Therapy (NSCL-E).",
        "destination_page": 85
    },
    {
        "source_page": 35,
        "anchor_text": "be considered (NSCL-12). testing with broad",
        "destination_page": 36
    },
    {
        "source_page": 35,
        "anchor_text": "nodules, please (DIAG-1).",
        "destination_page": 18
    },
    {
        "source_page": 35,
        "anchor_text": "tumors if both curable; see Evaluation (NSCL-1)",
        "destination_page": 24
    },
    {
        "source_page": 35,
        "anchor_text": "(NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 35,
        "anchor_text": "Advanced/metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 35,
        "anchor_text": "Initial Treatment (NSCL-12)",
        "destination_page": 36
    },
    {
        "source_page": 35,
        "anchor_text": "Findings (NSCL-4)",
        "destination_page": 27
    },
    {
        "source_page": 36,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 36,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). IGTA therapy (eg, cryotherapy, microwave,",
        "destination_page": 74
    },
    {
        "source_page": 36,
        "anchor_text": "Principles of Image-Guided Thermal Ablation Therapy (NSCL-D). medical oncology, and radiation oncology.",
        "destination_page": 84
    },
    {
        "source_page": 36,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 36,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 36,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 36,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 36,
        "anchor_text": "and Metastasis (NSCL-18) or",
        "destination_page": 42
    },
    {
        "source_page": 36,
        "anchor_text": "disease (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 37,
        "anchor_text": "CT scan is positive in the mediastinum, lymph Principles of Radiation Therapy (NSCL-C). If MRI is not possible, CT of head with contrast.",
        "destination_page": 74
    },
    {
        "source_page": 37,
        "anchor_text": "If MRI is not possible, CT of head with contrast. Concurrent Chemoradiation Regimens (NSCL-F). For patients who have received sequential chemoradiation,",
        "destination_page": 91
    },
    {
        "source_page": 37,
        "anchor_text": "(NSCL-8)",
        "destination_page": 32
    },
    {
        "source_page": 37,
        "anchor_text": "for Metastasis (NSCL-15) disease (NSCL-18)",
        "destination_page": 39
    },
    {
        "source_page": 37,
        "anchor_text": "(NSCL-15) or disease (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 37,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 38,
        "anchor_text": "pathologic confirmation. Principles of Radiation Therapy (NSCL-C). If MRI is not possible, CT of head with contrast.",
        "destination_page": 74
    },
    {
        "source_page": 38,
        "anchor_text": "If MRI is not possible, CT of head with contrast. Concurrent Chemoradiation Regimens (NSCL-F).",
        "destination_page": 91
    },
    {
        "source_page": 38,
        "anchor_text": "Biomarker (NSCL-19) Thoracentesis",
        "destination_page": 43
    },
    {
        "source_page": 38,
        "anchor_text": "disease solitary (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 38,
        "anchor_text": "Treatment for Stage IIIA (NSCL-7)",
        "destination_page": 31
    },
    {
        "source_page": 38,
        "anchor_text": "Treatment for Metastasis (NSCL-15) disease (NSCL-18)",
        "destination_page": 39
    },
    {
        "source_page": 38,
        "anchor_text": "(NSCL-15) or (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 38,
        "anchor_text": "Surveillance (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 39,
        "anchor_text": "Biomarker (NSCL-19) not previously",
        "destination_page": 43
    },
    {
        "source_page": 39,
        "anchor_text": "Advanced/metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 39,
        "anchor_text": "Treatment of Thoracic Disease",
        "destination_page": 40
    },
    {
        "source_page": 39,
        "anchor_text": "Treatment of Thoracic Disease (NSCL-16)",
        "destination_page": 40
    },
    {
        "source_page": 39,
        "anchor_text": "Thoracic Disease (NSCL-16)",
        "destination_page": 40
    },
    {
        "source_page": 39,
        "anchor_text": "Treatment of Thoracic Disease (NSCL-16)",
        "destination_page": 40
    },
    {
        "source_page": 39,
        "anchor_text": "Treatment of Thoracic Disease (NSCL-16)",
        "destination_page": 40
    },
    {
        "source_page": 39,
        "anchor_text": "Advanced/metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 40,
        "anchor_text": "metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 40,
        "anchor_text": "PET/CT and/or CT) positive mediastinum Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 40,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). IGTA therapy (eg, cryotherapy, microwave,",
        "destination_page": 74
    },
    {
        "source_page": 40,
        "anchor_text": "Principles of Image-Guided Thermal Ablation Therapy (NSCL-D).",
        "destination_page": 84
    },
    {
        "source_page": 40,
        "anchor_text": "IGTA therapy (eg, cryotherapy, microwave, radiofrequency) Concurrent Chemoradiation Regimens (NSCL-F). Chest CT with contrast and/or FDG-PET/CT to evaluate",
        "destination_page": 91
    },
    {
        "source_page": 40,
        "anchor_text": "Advanced/metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 40,
        "anchor_text": "metastatic (NSCL-19) and restagingz",
        "destination_page": 43
    },
    {
        "source_page": 41,
        "anchor_text": "(NSCL-G)",
        "destination_page": 93
    },
    {
        "source_page": 41,
        "anchor_text": "Therapy for Recurrence and Metastasis (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 41,
        "anchor_text": "Therapy for Recurrence and Metastasis (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 41,
        "anchor_text": "Recurrence (NSCL-18)",
        "destination_page": 42
    },
    {
        "source_page": 42,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C).",
        "destination_page": 68
    },
    {
        "source_page": 42,
        "anchor_text": "Principles of Surgical Therapy (NSCL-B). Principles of Radiation Therapy (NSCL-C). IGTA therapy (eg, cryotherapy, microwave,",
        "destination_page": 74
    },
    {
        "source_page": 42,
        "anchor_text": "Principles of Image-Guided Thermal Ablation Therapy (NSCL-D).",
        "destination_page": 84
    },
    {
        "source_page": 42,
        "anchor_text": "If MRI is not possible, CT of head with contrast. Concurrent Chemoradiation Regimens (NSCL-F). hh NCCN Guidelines for Central Nervous System Cancers.",
        "destination_page": 91
    },
    {
        "source_page": 42,
        "anchor_text": "chemoradiationn,t",
        "destination_page": 42
    },
    {
        "source_page": 42,
        "anchor_text": "Advanced/metastatic (NSCL-19) • Concurrent",
        "destination_page": 43
    },
    {
        "source_page": 42,
        "anchor_text": "disease (NSCL-19) (category 2B)",
        "destination_page": 43
    },
    {
        "source_page": 42,
        "anchor_text": "disease (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 42,
        "anchor_text": "(NSCL-15)",
        "destination_page": 39
    },
    {
        "source_page": 42,
        "anchor_text": "Advanced/metastatic (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 42,
        "anchor_text": "disease (NSCL-19)",
        "destination_page": 43
    },
    {
        "source_page": 43,
        "anchor_text": "Testing Results",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "Testing Results (NSCL-20)",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "Results (NSCL-20)",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "Testing Results",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "Testing Results (NSCL-20)",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "Results (NSCL-20)",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "Principles of Pathologic Review (NSCL-A). Temel JS, et al. N Engl J Med 2010;363:733-742.",
        "destination_page": 64
    },
    {
        "source_page": 43,
        "anchor_text": "treated as though they do not have driver oncogenes. Principles of Molecular and Biomarker Analysis (NSCL-H). Testing for HER2 IHC or c-Met/MET IHC is recommended",
        "destination_page": 95
    },
    {
        "source_page": 43,
        "anchor_text": "profiling is NSCL-20 and optimally",
        "destination_page": 44
    },
    {
        "source_page": 43,
        "anchor_text": "limited number (NSCL-I). biomarkers are",
        "destination_page": 103
    },
    {
        "source_page": 43,
        "anchor_text": "is a key Emerging",
        "destination_page": 103
    },
    {
        "source_page": 43,
        "anchor_text": "component of the improvement of care of patients with Biomarkers to Identify Patients for Therapies (NSCL-I). qq Lam VK, et al. Clin Lung Cancer 2019;20:30-36.e3; Sands",
        "destination_page": 103
    },
    {
        "source_page": 44,
        "anchor_text": "is guided by available results and, if unknown, these patients Principles of Molecular and Biomarker Analysis (NSCL-H).",
        "destination_page": 95
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-21",
        "destination_page": 45
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-24",
        "destination_page": 48
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-25",
        "destination_page": 49
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-26",
        "destination_page": 50
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-27",
        "destination_page": 51
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-30",
        "destination_page": 54
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-32",
        "destination_page": 56
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-33",
        "destination_page": 57
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-34",
        "destination_page": 58
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-35",
        "destination_page": 59
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-36",
        "destination_page": 60
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-37",
        "destination_page": 61
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-38",
        "destination_page": 62
    },
    {
        "source_page": 44,
        "anchor_text": "NSCL-39",
        "destination_page": 63
    },
    {
        "source_page": 45,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic",
        "destination_page": 95
    },
    {
        "source_page": 45,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 45,
        "anchor_text": "Molecular (NSCL-J). ss For performance",
        "destination_page": 104
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent Therapy (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent Therapy (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 45,
        "anchor_text": "Therapy, (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent Therapy (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 45,
        "anchor_text": "Subsequent (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 45,
        "anchor_text": "Therapy, (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 46,
        "anchor_text": "cryotherapy, microwave, radiofrequency) may be an option Principles of Image-Guided Thermal Ablation Therapy",
        "destination_page": 84
    },
    {
        "source_page": 46,
        "anchor_text": "for select patients. (NSCL-D). nn Principles",
        "destination_page": 84
    },
    {
        "source_page": 46,
        "anchor_text": "(NSCL-D). Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 46,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 46,
        "anchor_text": "Molecular (NSCL-J). Prophylactic",
        "destination_page": 104
    },
    {
        "source_page": 46,
        "anchor_text": "6%) and biopsy or plasma testing to Principles of Molecular and Biomarker Guidelines for Small Cell Lung Cancer.",
        "destination_page": 95
    },
    {
        "source_page": 46,
        "anchor_text": "evaluate mechanisms Analysis (NSCL-H) bbb Definitive local therapy",
        "destination_page": 95
    },
    {
        "source_page": 46,
        "anchor_text": "therapyddd,eee (NSCL-K 1 of 5) Cell Carcinoma",
        "destination_page": 110
    },
    {
        "source_page": 46,
        "anchor_text": "or Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 46,
        "anchor_text": "Subsequent (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 47,
        "anchor_text": "(eg, cryotherapy, microwave, radiofrequency) may be an option for Principles of Image-Guided Thermal Ablation Therapy (NSCL-D). Molecular and Biomarker Analysis (NSCL-H).",
        "destination_page": 84
    },
    {
        "source_page": 47,
        "anchor_text": "patients. See Principles of Image-Guided Thermal Ablation Therapy Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic",
        "destination_page": 95
    },
    {
        "source_page": 47,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 47,
        "anchor_text": "(approximately 6%) and biopsy or plasma testing to evaluate mechanisms Principles of Molecular and Biomarker Analysis (NSCL-H) Small Cell Lung Cancer.",
        "destination_page": 95
    },
    {
        "source_page": 47,
        "anchor_text": "(NSCL-K 1 of 5) 5)",
        "destination_page": 110
    },
    {
        "source_page": 47,
        "anchor_text": "Systemic therapyddd,eee Adenocarcinoma (NSCL-K Squamous Cell Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 47,
        "anchor_text": "(NSCL-22) Progression,",
        "destination_page": 46
    },
    {
        "source_page": 47,
        "anchor_text": "(NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 47,
        "anchor_text": "(NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 48,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic",
        "destination_page": 95
    },
    {
        "source_page": 48,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-22) Therapy (NSCL-23)",
        "destination_page": 46
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-22)",
        "destination_page": 46
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 48,
        "anchor_text": "Subsequent Subsequent Therapy (NSCL-23)",
        "destination_page": 47
    },
    {
        "source_page": 49,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic",
        "destination_page": 95
    },
    {
        "source_page": 49,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J). Response assessment after 2 cycles, then every 2–4 cycles",
        "destination_page": 104
    },
    {
        "source_page": 49,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or",
        "destination_page": 110
    },
    {
        "source_page": 49,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 49,
        "anchor_text": "Therapy (NSCL-K 3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 49,
        "anchor_text": "Subsequentkkk (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 49,
        "anchor_text": "Subsequentkkk (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 50,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic",
        "destination_page": 95
    },
    {
        "source_page": 50,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J). Response assessment after 2 cycles, then every 2–4 cycles",
        "destination_page": 104
    },
    {
        "source_page": 50,
        "anchor_text": "Systemic Therapy, Subsequentkkk (NSCL-K 4 of",
        "destination_page": 113
    },
    {
        "source_page": 50,
        "anchor_text": "Subsequentkkk (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 50,
        "anchor_text": "Maintenance Therapy",
        "destination_page": 112
    },
    {
        "source_page": 50,
        "anchor_text": "Maintenance Therapy (NSCL-K",
        "destination_page": 112
    },
    {
        "source_page": 50,
        "anchor_text": "Therapy (NSCL-K 3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 50,
        "anchor_text": "PD-L1 ≥1% (NSCL-38) PD-L1 <1%",
        "destination_page": 62
    },
    {
        "source_page": 50,
        "anchor_text": "PD-L1 <1% (NSCL-39)",
        "destination_page": 63
    },
    {
        "source_page": 51,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 51,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 51,
        "anchor_text": "Subsequent Therapy (NSCL-29)",
        "destination_page": 53
    },
    {
        "source_page": 51,
        "anchor_text": "Subsequent Therapy (NSCL-28)",
        "destination_page": 52
    },
    {
        "source_page": 51,
        "anchor_text": "Subsequent Therapy (NSCL-28)",
        "destination_page": 52
    },
    {
        "source_page": 51,
        "anchor_text": "Subsequent Therapy (NSCL-28)",
        "destination_page": 52
    },
    {
        "source_page": 51,
        "anchor_text": "Subsequent Therapy (NSCL-29)",
        "destination_page": 53
    },
    {
        "source_page": 52,
        "anchor_text": "therapyeee (NSCL-K 1 of 5) Carcinoma (NSCL-K",
        "destination_page": 110
    },
    {
        "source_page": 52,
        "anchor_text": "1 of 5) or (NSCL-K 2 of 5) Image-Guided Thermal Ablation",
        "destination_page": 111
    },
    {
        "source_page": 52,
        "anchor_text": "Cell Carcinoma (NSCL-K 2 of 5) Principles of Image-Guided Thermal Ablation Therapy (NSCL-D).",
        "destination_page": 84
    },
    {
        "source_page": 52,
        "anchor_text": "IGTA therapy (eg, cryotherapy, microwave, radiofrequency) Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 53,
        "anchor_text": "Therapy,eee (NSCL-K 1 of 5) Cell Carcinoma",
        "destination_page": 110
    },
    {
        "source_page": 53,
        "anchor_text": "or Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 53,
        "anchor_text": "cryotherapy, microwave, radiofrequency) may be an option Principles of Image-Guided Thermal Ablation Therapy",
        "destination_page": 84
    },
    {
        "source_page": 53,
        "anchor_text": "for select patients. (NSCL-D). nn Principles",
        "destination_page": 84
    },
    {
        "source_page": 53,
        "anchor_text": "(NSCL-D). Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 53,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease",
        "destination_page": 104
    },
    {
        "source_page": 53,
        "anchor_text": "Molecular (NSCL-J). ss For PS 0–4.",
        "destination_page": 104
    },
    {
        "source_page": 53,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or",
        "destination_page": 110
    },
    {
        "source_page": 53,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 54,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 54,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 54,
        "anchor_text": "Subsequent Therapy (NSCL-31)",
        "destination_page": 55
    },
    {
        "source_page": 54,
        "anchor_text": "Subsequent Therapy (NSCL-31)",
        "destination_page": 55
    },
    {
        "source_page": 54,
        "anchor_text": "Subsequent (NSCL-31)",
        "destination_page": 55
    },
    {
        "source_page": 55,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or",
        "destination_page": 110
    },
    {
        "source_page": 55,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 55,
        "anchor_text": "(NSCL-K 1 of 5) 5)",
        "destination_page": 110
    },
    {
        "source_page": 55,
        "anchor_text": "Adenocarcinoma (NSCL-K (NSCL-K 2 of 5) Principles of Image-Guided",
        "destination_page": 111
    },
    {
        "source_page": 55,
        "anchor_text": "Principles of Image-Guided Thermal Ablation Therapy (NSCL-D).",
        "destination_page": 84
    },
    {
        "source_page": 55,
        "anchor_text": "IGTA therapy (eg, cryotherapy, microwave, radiofrequency) Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 56,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic",
        "destination_page": 95
    },
    {
        "source_page": 56,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J). ss For PS 0–4.",
        "destination_page": 104
    },
    {
        "source_page": 56,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 56,
        "anchor_text": "or Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 56,
        "anchor_text": "Systemic Therapy, (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 56,
        "anchor_text": "Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 56,
        "anchor_text": "Systemic Therapy, (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 56,
        "anchor_text": "Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 56,
        "anchor_text": "Subsequent (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 57,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 57,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 57,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 57,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 57,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 57,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 57,
        "anchor_text": "Subsequent (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 57,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 57,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 57,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 57,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 57,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 57,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 57,
        "anchor_text": "Subsequent (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 58,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 58,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 58,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 58,
        "anchor_text": "Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 58,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 58,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 58,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 58,
        "anchor_text": "Squamous Cell (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 58,
        "anchor_text": "Subsequent (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 59,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 59,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J).",
        "destination_page": 104
    },
    {
        "source_page": 59,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 59,
        "anchor_text": "Squamous Cell (NSCL-K 2 of 5) or",
        "destination_page": 111
    },
    {
        "source_page": 59,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 59,
        "anchor_text": "Squamous Cell (NSCL-K 2 of 5) or",
        "destination_page": 111
    },
    {
        "source_page": 59,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 59,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 59,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 59,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 60,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 60,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J). Monitoring During Initial Therapy: Response assessment after 2 cycles, then every 2–4 cycles",
        "destination_page": 104
    },
    {
        "source_page": 60,
        "anchor_text": "within Guidelines parameters NSCL-K 4 of 5. definitions at oncokb.org.",
        "destination_page": 113
    },
    {
        "source_page": 60,
        "anchor_text": "Subsequentkkk (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 60,
        "anchor_text": "therapy (NSCL-K 3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 60,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or",
        "destination_page": 110
    },
    {
        "source_page": 60,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 61,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 61,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J). Monitoring During Initial Therapy: Response assessment after 2 cycles, then every 2–4 cycles",
        "destination_page": 104
    },
    {
        "source_page": 61,
        "anchor_text": "Subsequentkkk (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 61,
        "anchor_text": "therapy (NSCL-K 3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 61,
        "anchor_text": "Adenocarcinoma (NSCL-K 1 of 5) or",
        "destination_page": 110
    },
    {
        "source_page": 61,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 62,
        "anchor_text": "Principles of Molecular and Biomarker Analysis (NSCL-H). Molecular or Biomarker-Directed Therapy for Advanced or",
        "destination_page": 95
    },
    {
        "source_page": 62,
        "anchor_text": "Analysis (NSCL-H). for Advanced or Metastatic Disease (NSCL-J). PD-1/PD-L1 inhibitors may include active or previously",
        "destination_page": 104
    },
    {
        "source_page": 62,
        "anchor_text": "or L858R; ALK, RET, NSCL-K 1 of 5 (adenocarcinoma) pending, consider holding",
        "destination_page": 110
    },
    {
        "source_page": 62,
        "anchor_text": "rearrangements) have NSCL-K 2 of 5 for one cycle, unless",
        "destination_page": 111
    },
    {
        "source_page": 62,
        "anchor_text": "Systemic Therapyvvv (NSCL-K 1 of 5) Systemic Therapy,",
        "destination_page": 110
    },
    {
        "source_page": 62,
        "anchor_text": "Subsequentvvv (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 62,
        "anchor_text": "therapy (NSCL-J 2 of 6)",
        "destination_page": 105
    },
    {
        "source_page": 63,
        "anchor_text": "Systemic Therapy • Adenocarcinoma,",
        "destination_page": 110
    },
    {
        "source_page": 63,
        "anchor_text": "NSCLC NOS (NSCL-K 1 of 5) Squamous Cell",
        "destination_page": 110
    },
    {
        "source_page": 63,
        "anchor_text": "Carcinoma (NSCL-K 2 of 5)",
        "destination_page": 111
    },
    {
        "source_page": 63,
        "anchor_text": "Systemic Therapy, Subsequent (NSCL-K",
        "destination_page": 113
    },
    {
        "source_page": 63,
        "anchor_text": "Therapy, (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 63,
        "anchor_text": "Maintenance Therapy",
        "destination_page": 112
    },
    {
        "source_page": 63,
        "anchor_text": "Maintenance Therapy (NSCL-K",
        "destination_page": 112
    },
    {
        "source_page": 63,
        "anchor_text": "Therapy (NSCL-K 3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 63,
        "anchor_text": "Systemic Therapy, Subsequent (NSCL-K",
        "destination_page": 113
    },
    {
        "source_page": 63,
        "anchor_text": "Therapy, (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 63,
        "anchor_text": "Systemic Therapy, Progression",
        "destination_page": 113
    },
    {
        "source_page": 63,
        "anchor_text": "Progression (NSCL-K 4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 68,
        "anchor_text": "(NSCL-B 3 of 6)",
        "destination_page": 70
    },
    {
        "source_page": 68,
        "anchor_text": "The Role of Surgery (NSCL-B 3 of 6",
        "destination_page": 70
    },
    {
        "source_page": 68,
        "anchor_text": "Patients with N2 NSCL-B 5 of 6)",
        "destination_page": 72
    },
    {
        "source_page": 68,
        "anchor_text": "(NSCL-B 2 of",
        "destination_page": 69
    },
    {
        "source_page": 69,
        "anchor_text": "The Role of Surgery (NSCL-B 3 of 6",
        "destination_page": 70
    },
    {
        "source_page": 69,
        "anchor_text": "Patients with N2 NSCL-B 5 of 6)",
        "destination_page": 72
    },
    {
        "source_page": 69,
        "anchor_text": "(NSCL-B 3 of 6)",
        "destination_page": 70
    },
    {
        "source_page": 69,
        "anchor_text": "(NSCL-B 1 of 6)",
        "destination_page": 68
    },
    {
        "source_page": 70,
        "anchor_text": "to the initiation (NSCL-1,",
        "destination_page": 24
    },
    {
        "source_page": 70,
        "anchor_text": "initiation of NSCL-2,",
        "destination_page": 25
    },
    {
        "source_page": 70,
        "anchor_text": "therapy NSCL-3, Patients",
        "destination_page": 26
    },
    {
        "source_page": 70,
        "anchor_text": "since the NSCL-5, with occult-positive",
        "destination_page": 29
    },
    {
        "source_page": 70,
        "anchor_text": "presence NSCL-8, occult-positive",
        "destination_page": 35
    },
    {
        "source_page": 70,
        "anchor_text": "presence of mediastinal NSCL-11, occult-positive N2 nodes",
        "destination_page": 35
    },
    {
        "source_page": 70,
        "anchor_text": "mediastinal nodal NSCL-13, nodes discovered",
        "destination_page": 37
    },
    {
        "source_page": 70,
        "anchor_text": "disease has NSCL-14) at the time",
        "destination_page": 38
    },
    {
        "source_page": 70,
        "anchor_text": "NSCL-B 4 of 6",
        "destination_page": 71
    },
    {
        "source_page": 70,
        "anchor_text": "NSCL-B 5 of 6",
        "destination_page": 72
    },
    {
        "source_page": 75,
        "anchor_text": "NSCL-C 6 of 10 Gross tumor volume",
        "destination_page": 79
    },
    {
        "source_page": 75,
        "anchor_text": "NSCL-C 7 of 10) (GTV) comprises the",
        "destination_page": 80
    },
    {
        "source_page": 85,
        "anchor_text": "evaluated for preoperative therapy, with strong consideration for an immune Neoadjuvant Systemic Therapy for Patients Who Are Not Candidates for Immune",
        "destination_page": 87
    },
    {
        "source_page": 85,
        "anchor_text": "checkpoint inhibitor + Checkpoint Inhibitors. Test for PD-L1 status,",
        "destination_page": 87
    },
    {
        "source_page": 85,
        "anchor_text": "clinical and molecular factors to determine patients who may Principles of Molecular and Biomarker Analysis (NSCL-H). After surgical evaluation, patients ineligible for immunotherapy",
        "destination_page": 95
    },
    {
        "source_page": 85,
        "anchor_text": "adjuvant chemotherapy",
        "destination_page": 88
    },
    {
        "source_page": 85,
        "anchor_text": "Adjuvant Chemotherapy",
        "destination_page": 88
    },
    {
        "source_page": 85,
        "anchor_text": "Neoadjuvant Systemic Therapy for Patients Who Are Not Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 87
    },
    {
        "source_page": 85,
        "anchor_text": "Systemic Therapy Following Surgical Resection",
        "destination_page": 89
    },
    {
        "source_page": 85,
        "anchor_text": "Neoadjuvant Systemic Therapy in Patients Who Are Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 86
    },
    {
        "source_page": 86,
        "anchor_text": "nivolumab as adjuvant treatment after surgery (for Systemic Therapy Following Surgical Resection Nivolumab and hyaluronidase-nvhy subcutaneous",
        "destination_page": 89
    },
    {
        "source_page": 86,
        "anchor_text": "as adjuvant treatment after surgery (for patients Systemic Therapy Following Surgical Resection Platinum-doublet chemotherapy options include:",
        "destination_page": 89
    },
    {
        "source_page": 86,
        "anchor_text": "Neoadjuvant Systemic Therapy for Patients Who Are Not Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 87
    },
    {
        "source_page": 86,
        "anchor_text": "Systemic Therapy Following Surgical Resection",
        "destination_page": 89
    },
    {
        "source_page": 86,
        "anchor_text": "Adjuvant Chemotherapy",
        "destination_page": 88
    },
    {
        "source_page": 87,
        "anchor_text": "Adjuvant Chemotherapy",
        "destination_page": 88
    },
    {
        "source_page": 87,
        "anchor_text": "Systemic Therapy Following Surgical Resection",
        "destination_page": 89
    },
    {
        "source_page": 87,
        "anchor_text": "Neoadjuvant Systemic Therapy in Patients Who Are Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 86
    },
    {
        "source_page": 88,
        "anchor_text": "for PD-L1 status, EGFR mutations, and ALK rearrangements Principles of Molecular and Biomarker Analysis (NSCL-H).",
        "destination_page": 95
    },
    {
        "source_page": 88,
        "anchor_text": "Neoadjuvant Systemic Therapy for Patients Who Are Not Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 87
    },
    {
        "source_page": 88,
        "anchor_text": "Systemic Therapy Following Surgical Resection",
        "destination_page": 89
    },
    {
        "source_page": 88,
        "anchor_text": "Neoadjuvant Systemic Therapy in Patients Who Are Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 86
    },
    {
        "source_page": 89,
        "anchor_text": "for PD-L1 status, EGFR mutations, and ALK rearrangements Principles of Molecular and Biomarker Analysis (NSCL-H). Patients with completely resected tumors ≥4 cm or node-positive",
        "destination_page": 95
    },
    {
        "source_page": 89,
        "anchor_text": "Neoadjuvant Systemic Therapy for Patients Who Are Not Candidates for Immune Checkpoint Inhibitors Adjuvant Chemotherapy Neoadjuvant Systemic Therapy in Patients Who Are Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 87
    },
    {
        "source_page": 89,
        "anchor_text": "Neoadjuvant Systemic Therapy Adjuvant Chemotherapy",
        "destination_page": 88
    },
    {
        "source_page": 89,
        "anchor_text": "Neoadjuvant Systemic Therapy for Patients Who Are Not Candidates for Immune Checkpoint Inhibitors Neoadjuvant Systemic Therapy in Patients Who Are Candidates for Immune Checkpoint Inhibitors",
        "destination_page": 86
    },
    {
        "source_page": 93,
        "anchor_text": "Follow-up Care (NSCL-17)",
        "destination_page": 41
    },
    {
        "source_page": 95,
        "anchor_text": "biopsies, including “up-front” (NSCL-H 8 of 8).",
        "destination_page": 102
    },
    {
        "source_page": 96,
        "anchor_text": "NSCL-20 (NSCL-I). Tiered",
        "destination_page": 44
    },
    {
        "source_page": 96,
        "anchor_text": "in NSCL-20 (NSCL-I).",
        "destination_page": 103
    },
    {
        "source_page": 104,
        "anchor_text": "PD-L1 ≥50% First-Line Therapy",
        "destination_page": 105
    },
    {
        "source_page": 104,
        "anchor_text": "PD-L1 ≥1%–49% First-Line Therapy",
        "destination_page": 106
    },
    {
        "source_page": 105,
        "anchor_text": "Continuation Maintenance",
        "destination_page": 107
    },
    {
        "source_page": 105,
        "anchor_text": "PD-L1 ≥1%–49% First-Line Therapy",
        "destination_page": 106
    },
    {
        "source_page": 106,
        "anchor_text": "Continuation Maintenance",
        "destination_page": 107
    },
    {
        "source_page": 106,
        "anchor_text": "PD-L1 ≥50% First-Line Therapy",
        "destination_page": 105
    },
    {
        "source_page": 110,
        "anchor_text": "treatment for an actionable (NSCL-K 4 of 5). inhibitors may include",
        "destination_page": 113
    },
    {
        "source_page": 110,
        "anchor_text": "e Maintenance Therapy NSCL-K (3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 110,
        "anchor_text": "Subsequent Therapy NSCL-K (4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 111,
        "anchor_text": "actionable (NSCL-K 4",
        "destination_page": 113
    },
    {
        "source_page": 111,
        "anchor_text": "mutation, of 5).",
        "destination_page": 113
    },
    {
        "source_page": 111,
        "anchor_text": "Maintenance Therapy NSCL-K (3 of 5)",
        "destination_page": 112
    },
    {
        "source_page": 111,
        "anchor_text": "Subsequent Therapy NSCL-K (4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 112,
        "anchor_text": "Subsequent Therapy NSCL-K (4 of 5)",
        "destination_page": 113
    },
    {
        "source_page": 121,
        "anchor_text": "[链接在非文本对象上]",
        "destination_page": 3
    },
    {
        "source_page": 121,
        "anchor_text": "[链接在非文本对象上]",
        "destination_page": 121
    }
]